Literature DB >> 6606454

Amidolytic assay of human factor XI in plasma: comparison with a coagulant assay and a new rapid radioimmunoassay.

C F Scott, D Sinha, F S Seaman, P N Walsh, R W Colman.   

Abstract

The traditional coagulant assay for plasma factor XI suffers from a relatively high coefficient of variation, the need for rare congenitally deficient plasma, and a poor correlation between precision and sensitivity. We have developed a simple functional amidolytic assay for factor XI in plasma using the chromogenic substrate PyrGlu-Pro-Arg-p-nitroanilide (S-2366). After inactivation of alpha 1-antitrypsin, CI inhibitor, and other plasma protease inhibitors with CHCI3, plasma was incubated with kaolin, in the absence of added calcium, which limited the enzymes formed to those dependent on contact activation. Soybean trypsin inhibitor was used to minimize the action of kallikrein on the substrate. Once the reaction was complete, corn trypsin inhibitor was used to inactive factor XIIa, the enzyme generated by exposure of plasma to negatively charged surfaces, which had activated the factor XI. The assay is highly specific for factor XI, since plasma totally deficient in that zymogen yielded only 1%-3% of the enzymatic activity in normal plasma under identical conditions. The requirements for complete conversion of factor XI to XIa in plasma within 60 min were, respectively, factor XII, 0.6 U/ml, and high molecular weight kininogen, 0.2 U/ml. Prekallikrein was not an absolute requirement for complete activation but did accelerate the reaction. The intraassay coefficient of variation was 3.4%, and the mean of 35 normal plasmas was 1.00 U +/- 0.24 SD. In addition, a new rapid radioimmunoassay was devised using staphylococcal protein A as the precipitating agent for a complex of factor XI antigen with monospecific rabbit antibody. The mean was 1.01 U +/- 0.30 SD. The correlation coefficients for amidolytic versus coagulant and amidolytic versus radioimmunoassay were r = 0.95 for the former and 0.96 for the latter. Thus, a simple, accurate amidolytic assay and a radioimmunoassay have been devised for measuring factor XI in plasma that correlate well with the coagulant activity of factor XI, as determined in our laboratory.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6606454

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Recombinant alpha 1-antitrypsin Pittsburgh attenuates experimental gram-negative septicemia.

Authors:  R W Colman; D N Flores; R A De La Cadena; C F Scott; L Cousens; P J Barr; I B Hoffman; F Kueppers; D Fisher; S Idell
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

2.  Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies.

Authors:  H Akiyama; D Sinha; F S Seaman; E P Kirby; P N Walsh
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

3.  Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI.

Authors:  D Sinha; F S Seaman; A Koshy; L C Knight; P N Walsh
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

4.  Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX.

Authors:  P N Walsh; H Bradford; D Sinha; J R Piperno; G P Tuszynski
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

5.  Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate.

Authors:  C F Scott; R W Colman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

6.  Binding of high-molecular-mass kininogen to the Apple 1 domain of factor XI is mediated in part by Val64 and Ile77.

Authors:  F S Seaman; F A Baglia; J A Gurr; B A Jameson; P N Walsh
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

7.  Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.

Authors:  C F Scott; R W Carrell; C B Glaser; F Kueppers; J H Lewis; R W Colman
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.